StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.36−0.04 (-8.94%)

Close on Nov 17, 2026Market cap $87.79MP/E –Yield –

Outlook Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Outlook Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $17.36M, down 48.5% year over year. For fiscal 2025 it was $27.18M, down 34.9% from the year before. Over ten years it grew -3.5% a year on average. The highest annual figure on record is $42.33M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Sep 30, 2025$27.18M-34.9%
FY2024Sep 30, 2024$41.76M+57.9%
FY2023Sep 30, 2023$26.45M-37.5%
FY2022Sep 30, 2022$42.33M+8.7%
FY2021Sep 30, 2021$38.96M+47.9%
FY2020Sep 30, 2020$26.34M+10.7%
FY2019Sep 30, 2019$23.81M+28.6%
FY2018Sep 30, 2018$18.50M-22.3%
FY2017Sep 30, 2017$23.81M-27.3%
FY2016Sep 30, 2016$32.76M-15.7%
FY2015Sep 30, 2015$38.88M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$3.25M-54.4%
Q2 FY2026CQ1 2026Mar 31, 2026$4.50M+2.1%
Q1 FY2026CQ4 2025Dec 31, 2025$3.63M-62.4%
Q4 FY2025CQ3 2025Sep 30, 2025$5.98M-52.3%
Q3 FY2025CQ2 2025Jun 30, 2025$7.13M-36.3%
Q2 FY2025CQ1 2025Mar 31, 2025$4.41M-67.4%
Q1 FY2025CQ4 2024Dec 31, 2024$9.66M+113.3%
Q4 FY2024CQ3 2024Sep 30, 2024$12.52M+153.3%
Q3 FY2024CQ2 2024Jun 30, 2024$11.20M+0.9%
Q2 FY2024CQ1 2024Mar 31, 2024$13.51M+2378.9%
Q1 FY2024CQ4 2023Dec 31, 2023$4.53M-54.1%
Q4 FY2023CQ3 2023Sep 30, 2023$4.94M-45.0%
Q3 FY2023CQ2 2023Jun 30, 2023$11.10M+12.4%
Q2 FY2023CQ1 2023Mar 31, 2023$544.95K-94.5%
Q1 FY2023CQ4 2022Dec 31, 2022$9.86M-17.5%
Q4 FY2022CQ3 2022Sep 30, 2022$8.99M+17.9%
Q1 FY2022CQ4 2021Dec 31, 2021$9.87M+16.3%
Q4 FY2021CQ3 2021Sep 30, 2021$9.93M+126.7%
Q1 FY2021CQ4 2020Dec 31, 2020$11.95M+104.3%
Q4 FY2020CQ3 2020Sep 30, 2020$7.62M+2.3%
Q3 FY2020CQ2 2020Jun 30, 2020$8.49M+95.5%
Q2 FY2020CQ1 2020Mar 31, 2020$4.38M-26.2%
Q1 FY2020CQ4 2019Dec 31, 2019$5.85M-3.7%
Q4 FY2019CQ3 2019Sep 30, 2019$7.46M+4.3%
Q3 FY2019CQ2 2019Jun 30, 2019$4.34M-25.1%
Q2 FY2019CQ1 2019Mar 31, 2019$5.94M+15.1%
Q1 FY2019CQ4 2018Dec 31, 2018$6.07M+1408.8%
Q4 FY2018CQ3 2018Sep 30, 2018$7.15M+210.2%
Q3 FY2018CQ2 2018Jun 30, 2018$5.80M+39.4%
Q2 FY2018CQ1 2018Mar 31, 2018$5.16M+25.3%
Q1 FY2018CQ4 2017Dec 31, 2017$402.40K-97.0%
Q4 FY2017CQ3 2017Sep 30, 2017$2.30M-40.5%
Q3 FY2017CQ2 2017Jun 30, 2017$4.16M-65.4%
Q2 FY2017CQ1 2017Mar 31, 2017$4.12M-0.5%
Q1 FY2017CQ4 2016Dec 31, 2016$13.23M–
Q4 FY2016CQ3 2016Sep 30, 2016$3.87M–
Q3 FY2016CQ2 2016Jun 30, 2016$12.02M–
Q2 FY2016CQ1 2016Mar 31, 2016$4.14M–

More Outlook Therapeutics figures

See a number that looks wrong?